MDGL

MADRIGAL PHARMACEUTICALS, INC.

Healthcare

Biotechnology

Mkt cap: $11.82B

Madrigal Pharmaceuticals develops and commercializes Rezdiffra, an oral medication approved by the FDA and European Commission for treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease.

MADRIGAL PHARMACEUTICALS, INC is a Healthcare company operating in Biotechnology with a $11.82B market cap.

Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).

10 earnings calls indexed on Spoken Alpha.

Behavioral analysis

Management language signature

Disclosures

Investor Relations

Confidence: 0.80

ir.madrigalpharma.com

Extracted from Unknown source, 2026-06-21.

Transcripts

Recent earnings calls

Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.

All 10 calls

History

Earnings history

20 quarters

Q2 FY20262026-08-03
EPS— vs $-2.34
—
Rev— vs —
—
EODHD
Q1 FY20262026-05-11
EPS$-1.38 vs $-0.89
-55.0%
Rev$311.3M vs —
—
EODHD
Q4 FY20252026-02-18
EPS$-2.57

Track Record

Sample

Spoken Alpha tracks MDGL's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.

Beat rate

10/10

100%

Positive 1D reaction

4/10

40%

Avg 1D reaction

+0.1%

vs sector median

-0.4%

Healthcare

Beats consensus 10/10 quarters but stock falls 60% of the time

Sample

Top executives

Sample

Spoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.

Peers

Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.

API

For developers and AI agents

The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MDGL.

$ curl https://api.spokenalpha.com/v1/companies/MDGL

Get an API key API docs

FAQ

Frequently asked about MDGL

Where can I find MADRIGAL PHARMACEUTICALS, INC.'s (MDGL) earnings call transcripts?

Spoken Alpha indexes MDGL's earnings call transcripts at https://spokenalpha.com/companies/MDGL. Each call links to attributed speakers and parsed analyst Q&A. MADRIGAL PHARMACEUTICALS, INC.'s own investor relations page is at https://ir.madrigalpharma.com/.

When was MADRIGAL PHARMACEUTICALS, INC.'s most recent earnings call?

MADRIGAL PHARMACEUTICALS, INC. (MDGL) held its most recent earnings call on 2026-05-06, covering fiscal Q1 2026.

What sector is MDGL in?

MADRIGAL PHARMACEUTICALS, INC. (MDGL) operates in the Healthcare sector (Biotechnology industry).

Q3 FY2025

Earnings

2025-11-0416 Q&A exchanges

Q3 FY20252025-10-28

EPS$-4.96 vs $-3.36

-47.5%

Rev$287.3M vs —

—

EODHD

Q2 FY20252025-08-04

EPS$-1.90 vs $-3.63

+47.7%

Rev$212.8M vs —

—

EODHD

Q1 FY20252025-05-04

EPS$-3.32 vs $-6.28

+47.1%

Rev$137.3M vs —

—

EODHD

Q4 FY20242025-02-25

EPS$-2.71 vs $-4.12

+34.3%

Rev$103.3M vs —

—

EODHD

Q3 FY20242024-10-30

EPS$-4.92 vs $-6.91

+28.8%

Rev$62.2M vs —

—

EODHD

Q2 FY20242024-08-06

EPS$-7.10 vs $-7.53

+5.7%

Rev$14.6M vs —

—

EODHD

Q1 FY20242024-05-06

EPS$-7.38 vs $-6.28

-17.5%

Rev$0 vs —

—

EODHD

Q4 FY20232024-02-27

EPS$-5.68 vs $-5.28

-7.6%

Rev$770.0K vs —

—

EODHD

Q3 FY20232023-11-05

EPS$-5.34 vs $-4.93

-8.3%

Rev$0 vs —

—

EODHD

Q2 FY20232023-08-07

EPS$-4.69 vs $-4.58

-2.4%

Rev$0 vs —

—

EODHD

Q1 FY20232023-05-08

EPS$-4.23 vs $-4.94

+14.4%

Rev$0 vs —

—

EODHD

Q4 FY20222023-02-22

EPS$-4.98 vs $-4.56

-9.2%

Rev$0 vs —

—

EODHD

Q3 FY20222022-11-02

EPS$-4.75 vs $-4.15

-14.5%

Rev$0 vs —

—

EODHD

Q2 FY20222022-08-03

EPS$-4.14 vs $-3.70

-11.9%

Rev$0 vs —

—

EODHD

Q1 FY20222022-05-08

EPS$-3.36 vs $-3.62

+7.2%

Rev$0 vs —

—

EODHD

Q4 FY20212022-02-23

EPS$-3.78 vs $-3.88

+2.6%

Rev$37 vs —

—

EODHD

Q3 FY20212021-11-03

EPS$-3.79 vs $-3.90

+2.8%

Rev$8.3K vs —

—

EODHD

Period	Reported	EPS actual	EPS consensus	EPS surprise	Revenue actual	Revenue consensus	Rev. surprise	Source
Q2 FY2026	2026-08-03	—	$-2.34	—	—	—	—	EODHD
Q1 FY2026	2026-05-11	$-1.38	$-0.89	-55.0%	$311.3M	—	—	EODHD
Q4 FY2025	2026-02-18	$-2.57	$-0.60	-100.0%	$321.1M	—	—	EODHD
Q3 FY2025	2025-10-28	$-4.96	$-3.36	-47.5%	$287.3M	—	—	EODHD
Q2 FY2025	2025-08-04	$-1.90	$-3.63	+47.7%	$212.8M	—	—	EODHD
Q1 FY2025	2025-05-04	$-3.32	$-6.28	+47.1%	$137.3M	—	—	EODHD
Q4 FY2024	2025-02-25	$-2.71	$-4.12	+34.3%	$103.3M	—	—	EODHD
Q3 FY2024	2024-10-30	$-4.92	$-6.91	+28.8%	$62.2M	—	—	EODHD
Q2 FY2024	2024-08-06	$-7.10	$-7.53	+5.7%	$14.6M	—	—	EODHD
Q1 FY2024	2024-05-06	$-7.38	$-6.28	-17.5%	$0	—	—	EODHD
Q4 FY2023	2024-02-27	$-5.68	$-5.28	-7.6%	$770.0K	—	—	EODHD
Q3 FY2023	2023-11-05	$-5.34	$-4.93	-8.3%	$0	—	—	EODHD
Q2 FY2023	2023-08-07	$-4.69	$-4.58	-2.4%	$0	—	—	EODHD
Q1 FY2023	2023-05-08	$-4.23	$-4.94	+14.4%	$0	—	—	EODHD
Q4 FY2022	2023-02-22	$-4.98	$-4.56	-9.2%	$0	—	—	EODHD
Q3 FY2022	2022-11-02	$-4.75	$-4.15	-14.5%	$0	—	—	EODHD
Q2 FY2022	2022-08-03	$-4.14	$-3.70	-11.9%	$0	—	—	EODHD
Q1 FY2022	2022-05-08	$-3.36	$-3.62	+7.2%	$0	—	—	EODHD
Q4 FY2021	2022-02-23	$-3.78	$-3.88	+2.6%	$37	—	—	EODHD
Q3 FY2021	2021-11-03	$-3.79	$-3.90	+2.8%	$8.3K	—	—	EODHD

Source: EODHD. MDGL reported actuals as published; sparse fields render as —.

When a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.

Raised guidance 8 quarters in a row

Sample

Consecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.

Quarterly beats & misses

Sample

Q1 FY2026

$2.56 vs $2.07

+23.8%

1D -0.4%

Q4 FY2026

$2.54 vs $2.19

+15.9%

1D +3.2%

Q3 FY2026

$2.71 vs $2.14

+26.5%

1D -2.0%

Q2 FY2026

$2.47 vs $2.14

+15.2%

1D -4.2%

Q1 FY2025

$2.46 vs $2.16

+14.1%

1D -1.9%

Q4 FY2025

$2.57 vs $2.04

+26.2%

1D +4.9%

Q3 FY2025

$2.76 vs $2.30

+20.1%

1D +1.4%

Q2 FY2025

$2.53 vs $2.14

+18.2%

1D +2.5%

Q1 FY2024

$2.45 vs $2.16

+13.3%

1D -1.5%

Q4 FY2024

$2.78 vs $2.39

+16.3%

1D -0.6%

Quarter	Actual EPS	Consensus	Surprise	1D	5D
Q1 FY2026	$2.56	$2.07	+23.8%	-0.4%	-2.0%
Q4 FY2026	$2.54	$2.19	+15.9%	+3.2%	+3.4%
Q3 FY2026	$2.71	$2.14	+26.5%	-2.0%	-3.5%
Q2 FY2026	$2.47	$2.14	+15.2%	-4.2%	-6.6%
Q1 FY2025	$2.46	$2.16	+14.1%	-1.9%	-0.6%

Guidance change history

Sample

Q1 FY2026
Raised
2026-04-15
Q4 FY2026
Raised
2026-13-15
Q3 FY2026
Raised
2026-10-15
Q2 FY2026
Raised
2026-07-15
Q1 FY2025
Raised
2025-04-15
Q4 FY2025
Raised
2025-13-15
Q3 FY2025
Raised
2025-10-15
Q2 FY2025
Raised
2025-07-15

CFO since 2025 • 3/4 beats (75%) • last guidance cut Q3 FY2026

BullFrog AI Holdings, Inc.

Overview

Management language signature

Investor Relations

Recent earnings calls

Earnings history

Track Record

Top executives

Other companies in Healthcare

For developers and AI agents

Frequently asked about MDGL

Quarterly beats & misses

Guidance change history